Summary
The serum levels of osteocalcin, a 49-amino-acid bone-matrix protein, which is a biochemical parameter of bone formation, were measured in 61 patients with breast cancer. Breast cancer patients were subdivided as follows: (a) Patients in complete remission; (b) patients with visceral metastases (without bone metastases); (c) patients with bone metastases (with or without visceral metastases). Serum osteocalcin levels were significantly higher in patients with bone metastases than in patients in complete remission (P<0.005). When osteocalcin levels of patients with bone metastases were compared with those of an age-matched control group, serum osteocalcin levels were higher in the patients with bone metastases; however, the differences did not reach statistical significance. Serum osteocalcin levels of patients with visceral metastases (without bone metastases) were significantly lower than in control subjects (P<0.02). Our data demonstrate that serum osteocalcin levels are higher in breast cancer patients with bone metastases than in patients in remission. Bone formation, as reflected by serum osteocalcin levels, is decreased in breast cancer patients with visceral metastases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ (1984) Serum bone GLA-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1:1091
Carrasco MG, Gruson M, De Vernejoul MC, Denne MA, Miravet L (1988) Osteocalcin and bone morphometric parameters in adults without bone disease. Calcif Tissue Int 42:13–17
Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, Rubens RD (1988) Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 24:1211–1217
Deftos LJ, Parthemore G, Price A (1982) Canges in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int 34:121–124
Deimas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ (1986) Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. J Clin Invest 77:985–991
Garrel DR, Delmas PD, Malaval L, Tourniaire J (1986) Serum Bone GLA protein: A marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 62:1052
Lukert BP, Higgins JC, Stoskopf MM (1986) Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 62:1056
Niell HB, Neely CL, Palmieri GM, McDonald MW (1983) The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer. Am Cancer 52:1442–1447
Pietschmann P, Woloszczuk W, Panzer S, Kyrle P, Smolen J (1988) Decreased serum osteocalcin levels in phenprocoumon-treated patients. J Clin Endocrinol Metab 66:1071–1074
Price PA, Parthemore JG, Deftos LJ (1980) New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 66:878
Slovik DM, Gundberg CM, Neer RM, Lian JB (1984) Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab 59:228
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pietschmann, P., Zielinski, C. & Woloszczuk, W. Serum osteocalcin levels in breast cancer patients. J Cancer Res Clin Oncol 115, 456–458 (1989). https://doi.org/10.1007/BF00393337
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00393337